On October 2, CANSINOBIO fell 5.53% at open, trading at HK$34.52/share, with turnover of HK$897,500. The decline follows a correction after the stock's cumulative closing price deviation exceeded 30% over three consecutive trading days, triggering an abnormal trading volatility notice.

The company issued an announcement emphasizing that no material information requiring disclosure has been withheld, and that directors and senior management did not trade company shares during the abnormal volatility period. The prior surge was primarily driven by Moderna's announcement that its mRNA neoantigen therapy data would be presented at the ESMO conference in Madrid later this month, combined with CANSINOBIO's strategic partnership with deepGeneAI to co-develop personalized mRNA therapeutic cancer vaccines targeting gastrointestinal solid tumors and rare cancers.

The broader biotech sector is trading under pressure, with BEONE Medicines down 5.68% and Innovent Bio down 3.93%, intensifying short-term profit-taking sentiment following the sharp rally. CLSA previously noted that CANSINOBIO's mRNA development pipeline broadly mirrors Moderna's approach, representing a potential platform-level revaluation opportunity.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)